NCT03768960 2025-02-03
A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Johnson & Johnson Private Limited
Phase 4 Completed